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Objectives: To investigate the relative pathogenicity of Candida albicans treated with subinhibitory
concentrations of fluconazole in a mouse model of disseminated candidiasis. Previous studies indicate
that these cells secrete 10 times more farnesol than do untreated cells. In our usage, subinhibitory means
a concentration which causes a prominent decrease in turbidity but still allows some cell growth.
Methods: C. albicans A72 cells were grown overnight in 0–5.0 mM fluconazole, washed, and inoculated in
mice by tail vein injection. Groups of 15 or 16 mice were injected with 1.3 · 106 cells and mortality was
recorded for 7 days post-inoculation. The levels of farnesol in control and treated C. albicans were deter-
mined by GC/MS.
Results: The MIC50 for strain A72 was 0.125 mg/L (0.4 mM). Mice administered C. albicans pre-treated with
0.5 to 1.0mMfluconazoledied2.5 to 4daysearlier andhad2 to4 timeshighermortality rates thanmicegiven
untreated C. albicans. Fluconazole (0.5 to 1.0 mM) pre-treated cells were 4.2 to 8.5 times more lethal (P <
0.001) thanuntreatedcells.Theextracellular,membranebound,and intracellular farnesolconcentrationsof
cells pre-treated with 1.0 mM fluconazole were 12-, 2- and 6-times those of untreated cells.
Conclusions: The effects of fluconazole on C. albicans are very concentration-dependent. The enhanced
pathogenicity of fluconazole pre-treated C. albicans in mice should be relevant to the therapeutic and
prophylactic use of fluconazole. Further research is needed to explore whether farnesol production by
C. albicans is a virulence factor.
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Introduction
The dimorphic fungus Candida albicans is one of the most com-
mon fungal pathogens of humans. Candidiasis associated with
C. albicans is primarily an opportunistic infection of immuno-
compromised patients.1 Additionally, infections with C. albicans
account for 78% of fungal nosocomial infections, representing over
10% of all nosocomial infections in the USA.1 The annual cost of
treating candidiasis in the United States has been estimated at one
billion dollars.2 Fluconazole is the most common antifungal drug
prescribed by practitioners and it has been the drug of choice for
mucosal and disseminated candidiasis.3 Fluconazole is also a rec-
ommended prophylactic drug to prevent fungal invasion in
leucopenic patients3,4 and to avoid opportunistic and nosocomial
candidiasis in AIDS patients.4 The mode of action of fluconazole
involves inhibition of lanosterol 14a demethylase in ergosterol
biosynthesis.5 Previous work in our laboratory has shown that
C. albicans excretes farnesol, a C15-isoprenoid, and that exogenous
farnesol prevents mycelial development in both a growth morphol-
ogy assay and a differentiation assay.6 Thus, in the presence of
farnesol, C. albicans appears as actively budding yeasts without
influencing cellular growth rates.6 C. albicans synthesizes farnesol
from farnesyl pyrophosphate (FPP).7 Because FPP is the biosyn-
thetic precursor of both farnesol7 and ergosterol,5 we hypothesized
that drugs blocking the sterol biosynthetic pathway after FPP
might lead to the accumulation of FPP, which, in turn, could
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lead to enhanced farnesol production. This hypothesis proved to be
correct; treatment of C. albicans with subinhibitory concentrations
of either zaragozic acid B or fluconazole resulted in 8-fold7 and 10-
fold8 increases, respectively, in the amount of farnesol produced by
C. albicans. A similar response was observed whenC. albicanswas
treated with three other azole antifungals.8
Since all of our previous work had been done in vitro, we were
interested in extending the effect of fluconazole treatment and
farnesol production to a mouse model of disseminated infection.
We hypothesized that by virtue of its effect on farnesol biosynthe-
sis, treatment of C. albicans with subinhibitory concentrations
of fluconazole before parenteral administration might affect the
outcome of the infection. The concept that growth conditions influ-
ence C. albicans virulence in the host has precedent. Antley and
Hazen9 showed that cells grown at room temperature are signifi-
cantly more virulent than cells grown at 37C. Here we show that
mice intravenously administered C. albicans pre-treated with
subinhibitory concentrations of fluconazole died significantly earl-
ier and had higher mortality rates than mice in control groups
administered untreated C. albicans.
Materials and methods
C. albicans strain, growth conditions and
fluconazole treatment
C. albicans strain A72 was kindly provided by Patrick A. Sullivan,
University of Otago, New Zealand. It is available as ATCC
MYA-2430, Rockville, MD, USA. It is a well characterized far-
nesol-producing and farnesol-responsive strain that has been used in
previous in vitro studies.6–8 In this regard, it is typical of other labor-
atory and clinical isolates of C. albicans.8 The fluconazole MIC values
for strain A72were determined by standard NCCLSM27 protocol10 by
the Fungus Testing Laboratory (San Antonio, TX, USA). For chal-
lenge, C. albicans cells were grown overnight in 50 mL of modified
glucose/salts/biotin (mGSB) medium at 30C with aeration as previ-
ously described.6 For fluconazole pre-treatment, C. albicans cells
were grown overnight (16 h) in 50mL ofmGSBmedium supplemented
with fluconazole (gift from Pfizer Pharmaceuticals, Sandwich, UK) at
0, 0.25, 0.5, 1.0 or 5.0 mM. All of the cells had a typical yeast mor-
phology. Control and treated cells were harvested by centrifugation at
4750 g for 10 min, washed once with 50 mL of sterile, non-pyrogenic
normal saline (Abbott Laboratories, North Chicago, IL, USA) and
resuspended in 10 mL of saline before measuring cell numbers with
a Petroff-Hausser counting chamber. These cell suspensions were
adjusted to the final concentration in non-pyrogenic sterile saline
for parenteral administration. Viability was assessed by determining
the number of cfu per mL of dilutions of 0.1 mL samples of treated
and untreated cell suspensions plated in triplicate on BiGGY agar
(BBL, Becton Dickinson, Sparks, MD, USA),11 and counting after
48 h of incubation at 30C.
Determination of farnesol in C. albicans fractions
C. albicans A72 was grown for 24 h at 25C or 30C in 100 mL of
mGSB medium6 with and without 1.0 mM fluconazole. The cells were
harvested by centrifugation at 4100 g for 5 min at 25C. The pellets
were washed once and resuspended in distilled water. Dry weights
were determined using pre-weighed watch glasses and baking the
samples in an oven at 180C for 1 h. Extracellular farnesol was anal-
ysed by gas chromatography/mass spectroscopy (GC/MS) as previ-
ously described.6,8 To determine intracellular farnesol, the cell pellets
were mixed with 5 g of 0.5 mm glass beads and the cells were disrupted
by vortexing for 3 min. Cell breakage was greater than 95% as
determined by microscopic examination. Cell debris was collected
by centrifugation at 4100 g for 5 min at 25C and the supernatants
with the intracellular farnesol were treated and analysed as referenced
for the extracellular fraction. To determine the amount of farnesol in
the cellular membranes, the cell debris from above was extracted
directly into 100% ethyl acetate and vortexed for 3 min. The samples
were centrifuged at 11 400 g for 20 min at 25C and the resulting
supernatants (ethyl acetate) were analysed as described previously.6,8
Saponification of the remaining, ethyl acetate extracted membrane
fractions gave no further release of farnesol.
Mice and mouse inoculation
Outbred, 4- to 6-week-old (20–25 g), CF-1 female mice (Charles
River Laboratories, Wilmington, MA, USA) were randomly allocated
to groups of five or six mice in polycarbonate cages with stainless steel
wire tops. After a 7- to 10-day acclimatization period, groups of mice
were inoculated with 0.1 mL containing the appropriate numbers of
C. albicans by intravenous (iv) injection in the lateral caudal tail vein
using a 27 gauge needle. Clinical signs of illness were monitored four
times daily. The experimental protocol, housing, and care of the mice
were in accordance with approved guidelines of the University of
Nebraska–Lincoln Institutional Animal Care and Use Committee.
Experimental design
The LD50 value for C. albicans A72 at day three post-inoculation (PI)
was 1.0 · 107 cells. Therefore to increase the likelihood of observing a
difference in lethality between control and treated C. albicans, mice
were inoculated with a sub-lethal challenge consisting of 1.3 · 106
cells, in all subsequent experiments. Initial experiments (Trial 1) exam-
ined the effect of pre-treatment ofC. albicanswith 1.0 mM fluconazole
on mouse survival post-challenge. Groups of 15 mice each were inocu-
lated with either untreated C. albicans or C. albicans pre-treated with
fluconazole and clinical signs were monitored for 7 days PI. Additional
experiments (Trial 2) examined the effect of pre-treatment of
C. albicans with increasing concentrations of fluconazole, 0, 0.25,
0.5, 1.0 and 5.0 mM, on mouse survival post-challenge. In this experi-
ment, groups of 16 mice each were inoculated with sub-lethal numbers
of either control untreated C. albicans or C. albicans pre-treated with
fluconazole andmonitored for 7 days PI. In each experiment, a group of
five mice inoculated with saline without C. albicans served as a nega-
tive control.
Statistical analysis
The main parameter measured was the time (h) from iv inoculation
to death or euthanasia because of severe clinical signs. The data
were plotted as Kaplan–Meier survival curves and analysed using
LIFETEST and proportional hazards regression (PHREG) proce-
dures.12 The LIFETEST assesses model assumptions using three non-
parametric tests, Log-rank, Wilcoxon and Likelihood ratio tests, to
determine whether two or more treatment groups are different.
PHREG performs Cox regression of survival data using proportional
hazards model. The resulting regression coefficients are an estimate of
the exponent of the hazard ratios or relative risk.
Results and discussion
Cellular farnesol in C. albicans treated with fluconazole
The fluconazole pre-treated cells used in our mouse inoculations
had been washed in sterile saline prior to injection to remove all
extracellular fluconazole and farnesol. However, the washed cells
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still contained high cellular concentrations of farnesol (Table 1).
Following pre-treatment with 1.0 mM fluconazole, the concentra-
tions of intracellular and membrane-associated farnesol increased
6-fold and 2-fold, respectively (Table 1). Therefore, the flucona-
zole pre-treated cells appeared pre-programmed to release higher
levels of farnesol than untreated cells.
Mouse lethality of C. albicans pre-treated with fluconazole
C. albicans pre-treated with 0 to 5 mM fluconazole were compared
for their pathogenicity in themousemodel. The 0.5 and 1.0 mMpre-
treated cells displayed enhanced lethality when compared with
untreated cells. The onset of mortality was 60–90 h sooner and
by day 5 PI they showed 6- to 8-fold higher mortality than mice
inoculated with untreated cells (Figure 1). As expected, control
mice inoculated with saline alone had no mortality on day 7 PI.
The data were analysed according to the Log-rank, Wilcoxon and
Likelihood ratio tests. All three tests revealed that the survival
curves for the 0.5 and 1.0 mM fluconazole pre-treated cells were
different from the survival curves for the control cells (P < 0.001).
The 0.5 and 1.0 mM pre-treated survival curves were not different
from each other, but they were both significantly different (P <
0.01) from the 0.25 and 5.0 mM pre-treated groups. Furthermore,
from the PHREG, hazard ratio estimates of 8.454 and 95% con-
fidence interval (2.308–30.965), indicated that the 0.5 and 1.0 mM
fluconazole pre-treated cells had 4.7 and 4.2 times higher lethality
than the untreated cells, respectively. A separate trial which only
used 1.0 mM fluconazole showed that the fluconazole pre-treated
cells had 8.5 times higher lethality than untreated cells (Figure 1).
Interestingly, the concentrations of fluconazole that caused
8.5-fold greater mouse lethality (0.5–1.0 mM) coincided precisely
with those that caused maximal enhancement of farnesol produc-
tion in vitro.8
Viability of fluconazole-treated cells
The cells which had been pre-treated with 0.25 or 5.0 mM flucona-
zole showed no enhanced lethality (Figure 1). Low doses of
fluconazole (0.25 mM) might not have inhibited lanosterol 14a
demethylase sufficiently to result in detectable farnesol accumu-
lation,8 whereas the cells pre-treated with the highest concentration
of fluconazole (5.0 mM) might have been unable to replicate in
mice and therefore were eliminated rapidly. In keeping with the
fact that fluconazole is fungistatic rather than fungicidal,5,8 cells
pre-treated with fluconazole (0.25–5.0 mM) were still viable by
plate count assays. C. albicans cells pre-treated with 0, 0.25, 0.5,
1.0 or 5.0 mM fluconazole showed 7.3 · 106, 6.1 · 106, 4.4 · 106,
2.0 · 106 and 9.0 · 105 cfu/mL, respectively. For reference, the
MIC50 value at both 24 and 48 h for C. albicans A72 towards
fluconazole was 0.125 mg/L (0.41 mM). This MIC represents
the lowest concentration which prominently decreased turbidity10
and a value of 0.125 mg/L indicates that strain A72 is highly
susceptible to fluconazole.4 We previously showed that 4–8 mg/L
(13–26 mM) fluconazole prevented growth entirely.13
The observation that subinhibitory concentrations of flucona-
zole enhance virulence might be relevant to the therapeutic use of
fluconazole as well as prolonged, prophylactic administration of
fluconazole and to otherwise unexplained failures of fluconazole
treatment in certain patients.3,5 The potential side effects of expo-
sure of C. albicans to subinhibitory concentrations of fluconazole
have not been investigated previously. Exposure to subinhibitory
concentrations of fluconazole correlated with an increased concen-
tration of intracellular farnesol in C. albicans treated cells. There-
fore, we propose that the fungal quorum sensing molecule farnesol
might indirectly play a role in the pathogenesis of disseminated
candidiasis. Farnesol is not an innocuous molecule. It has been
reported to influence mammalian cells in several ways,14 including
blocking calcium channels, triggering apoptosis, targeting HMG
CoA reductase for degradation, and stimulating cell differentiation.
Thus, future research aimed at determining the role of farnesol and
quorum sensing in disseminated candidiasis is needed.
Alternatively, the mechanism of fluconazole-induced enhanced
lethality of C. albicans might not involve farnesol and thus the
changes in intracellular farnesol would be coincidental. Exposure
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Figure 1. Effect of pre-treatment ofC. albicanswith fluconazole on the survival
of mice inoculated intravenously at time 0 with a sub-lethal dose of C. albicans
cells (1.3 · 106). All data shown are for Trial 2 except the filled diamonds for
1.0 mM fluconazole. Symbols: open squares, 0.25 mM fluconazole; filled trian-
gles, 0.5 mM fluconazole; filled diamonds, 1.0 mM fluconazole (Trial 1); open
inverted triangles, 1.0 mM fluconazole; open circles, 5.0 mM fluconazole; filled
circles, untreated C. albicans (both trials). A control group consisting of five
mice inoculated with saline intravenously had no mortality on day 7 post-
inoculation (data not shown). For the last two time points, the filled triangle
and open inverted triangle data coincide. The two controls with untreated
C. albicans (both n = 15) conducted 2 months apart gave identical results.
Table 1. Increased farnesol production by fluconazole-
treated cells
Farnesol (mg/g dry weight)a
Farnesol location no fluconazole 1.0 mM fluconazole
Extracellular 0.115 – 0.023 1.40 – 0.595
Intracellular 0.009 – 0.007 0.054
Membrane-associated 0.106 – 0.032 0.208
aValues for untreated cells and extracellular fluconazole-treated cells are
the average of seven experiments with standard deviations shown. The
intracellular and membrane-associated samples for cells treated with 1 mM flu-
conazole are the average of two experiments agreeingwithin –10%. The 12-fold
increase in extracellular farnesol by fluconazole-treated cells agrees with
previously reported values.8 In the units for extracellular farnesol (mg/g dry




of C. albicans to subinhibitory concentrations of fluconazole can
affect the expression of virulence determinants such as the secret-
ory aspartyl proteinases (SAPs). For C. albicans isolates obtained
from an AIDS patient both before and after the development
of fluconazole resistance, it was found that the fluconazole-
susceptible isolates had a dose-dependent decrease in extracellular
SAP activity whereas the fluconazole-resistant isolates had a
dose-dependent increase in SAP activity.15 It was suggested that
patients infected with fluconazole-resistant isolates of C. albicans
may have enhanced virulence when exposed to subinhibitory con-
centrations of fluconazole.15
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